COMMUNIQUÉS West-GlobeNewswire

Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018

13/04/2018 - 14:02

Synergy of CB-839 with CDK4/6 and PARP inhibitors SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on the [...]

Ceapro Inc. to Present at the 12th International Symposium on Supercritical Fluids

13/04/2018 - 14:00

EDMONTON, Alberta, April 13, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO ) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients [...]

Abiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call Notification

13/04/2018 - 14:00

DANVERS, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ: ABMD ) announced that on Thursday, May 3, 2018, the Company will release financial results for the fourth quarter of fiscal 2018. The Company [...]

CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

13/04/2018 - 14:00

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]

Olerup QTYPE® Receives CE Mark Certification

13/04/2018 - 14:00

Fastest real time typing with Olerup QTYPE is now broadly available BRISBANE, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ), a molecular diagnostics company focused on the discovery, [...]

BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair

13/04/2018 - 13:19

ANAHEIM, CA, April 13, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addition, today announced that the [...]

Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

13/04/2018 - 13:00

11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA) NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT [...]

EyeGate Announces $11.25 Million Public Offering

13/04/2018 - 13:00

WALTHAM, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG ) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform [...]

Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia

13/04/2018 - 13:00

Six abstracts support lefamulin as a potential first-in-class pleuromutilin antibiotic targeting CABP pathogens, including drug resistant phenotypes DUBLIN, Ireland, April 13, 2018 (GLOBE NEWSWIRE) -- Nabriva [...]

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)

13/04/2018 - 13:00

La Chaux-de-Fonds, Switzerland, April 13, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Tenalisib (RP6530 [...]

Shire plc: Form 8 Opening Position Disclosure - Takeda Pharmaceutical Company Limited

13/04/2018 - 12:51

FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Shire plc (b) Owner or controller of interests [...]

Shire plc: Form 8 Opening Position Disclosure - Shire plc

13/04/2018 - 12:46

FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Shire plc (b) Owner or controller of interests [...]

MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France

13/04/2018 - 12:30

LA JOLLA, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Aino Health AB (publ): Aino Health AB signs cooperation agreement with Attendo

13/04/2018 - 10:38

Aino Health and Attendo Health Care Services have signed a cooperation agreement regarding Aino's HealthManager platform. With Aino's HealthManager, Attendo extends its portfolio for corporate health management [...]

Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018

13/04/2018 - 10:24

Company Release no. 09/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 April 2018 Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018 Summary: At Veloxis Pharmaceuticals A/S’ Annual General [...]

BIOHIT OYJ’S OWNERSHIP IS EXPANDING

13/04/2018 - 08:30

Biohit Oyj Stock Exchange Release April 13, 2018 at 9:30 am local time (EEST) The company has become aware that Biohit Oyj’s ownership is possibly expanding. With the possible trade of shares, Biohit Oyj’s partner [...]

Shire plc : Rule 2.9 Announcement

13/04/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 13 April 2018 [...]

Kiadis Pharma announces Annual Results for the year ended December 31, 2017

13/04/2018 - 07:01

Kiadis Pharma announces Annual Results for the year ended December 31, 2017 Significantly strengthened cash position; raised over EUR 60 million in equity and debt (gross, including raise in March 2018) Filed Marketing [...]

Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million

13/04/2018 - 03:24

SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“ Immutep ” or the “ Company ”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April 2018. The [...]